Literature DB >> 30422400

Characteristics of metabolic stability and the cell permeability of 2-pyrimidinyl-piperazinyl-alkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione with antidepressant- and anxiolytic-like activities.

Agnieszka Zagórska1, Anna Partyka2, Adam Bucki1, Marcin Kołaczkowski1, Magdalena Jastrzębska-Więsek2, Anna Czopek1, Agata Siwek3, Monika Głuch-Lutwin4, Marek Bednarski4, Marek Bajda5, Jakub Jończyk5, Kamil Piska6, Paulina Koczurkiewicz6, Anna Wesołowska2, Maciej Pawłowski1.   

Abstract

A series of 2-pyrimidinyl-piperazinyl-alkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione has been synthesized in an attempt to discover a new class of psychotropic agents. Compounds were evaluated for their in vitro affinity for serotonin 5-HT1A , 5-HT7 , and phosphodiesterases PDE4 and PDE10. The most potent compound 2-pyrimidinyl-1-piperazinyl-butyl-imidazo[2,1-f]purine-2,4-dione (4b) behaved as strong and selective antagonist of 5-HT1A . Molecular modeling studies revealed differences in binding mode between compound 4b and buspirone, which might reflect variation of the ligands' affinity and potency in the 5-HT1A receptor. Compound 4b in silico models demonstrated drug-likeness properties and, contrary to buspirone, showed a metabolic stability in mouse liver microsomes system. Experimentally obtained value of apparent permeability coefficient Papp for 4b in parallel artificial permeability assay indicates the possibility of binding weakly to plasma proteins and high intestinal absorption fraction. Evaluation of the antidepressant- and anxiolytic-like activities of 4b revealed both activities at the same dose of 1.25 mg/kg and seemed to be specific. The antidepressant and/or anxiolytic properties of 4b may be related to its first-pass effect.
© 2018 John Wiley & Sons A/S.

Entities:  

Keywords:  PDE inhibitors; antidepressants; anxiolytics; buspirone; serotonin receptors ligands

Mesh:

Substances:

Year:  2018        PMID: 30422400     DOI: 10.1111/cbdd.13442

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  1 in total

1.  A new FGFR inhibitor disrupts the TGF-β1-induced fibrotic process.

Authors:  Mi-Hyoung Kim; Seung-Youn Jung; Kyung-Hee Song; Jeong-In Park; Jiyeon Ahn; Eun-Ho Kim; Jong Kuk Park; Sang-Gu Hwang; Hee-Jong Woo; Jie-Young Song
Journal:  J Cell Mol Med       Date:  2019-11-06       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.